Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 3;47(6):1782–1794. doi: 10.1093/schbul/sbab066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 4. — sRAGE level is decreased after 6-mo NAC add-on treatment in EP patients and is associated with increased GABA level in the PFCx, as well as improvements in cognition and positive symptoms. (A) sRAGE decrease in the NAC-treated group (N = 18; P < .0001) compared to the placebo group (N = 18). (B) Negative correlation between delta GABA and delta sRAGE in NAC-treated group (N = 9; r = −0.68, P = .04). (C) Negative correlation between delta processing speed and delta sRAGE in NAC-treated group (N = 11; r = −0.59, P = .05). (D) Negative correlation between delta PANSS positive symptoms and delta sRAGE in NAC-treated group (N = 13; r = −0.6, P = .02).